Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtezoTRIBE2
2023-506632-32-00Phase 3Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, bevacizumab, irinotecan, oxaliplatin, fluorouracil and 1 more in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Progression-free survival. Planned start Aug 2024; status: authorised.
02
Drugs
atezolizumabbevacizumabirinotecanoxaliplatinfluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2023-506632-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506632-32-00.